Precision Biosciences (DTIL) Cash from Financing Activities (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Cash from Financing Activities data on file, last reported at $745000.0 in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $745000.0, down 93.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $85.2 million (up 305.0% YoY), and the FY2025 annual result was $95.2 million, up 88.63% from the prior year.
• Cash from Financing Activities fell to $745000.0 in Q1 2026 per DTIL's latest filing, from $77.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $92.9 million in Q2 2022 and troughed at -$180000.0 in Q3 2022.
• A 5-year average of $15.4 million and a median of $2.5 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 101.51% in 2022, then surged 11079.41% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$180000.0 in 2022, then soared by 1671.11% to $2.8 million in 2023, then soared by 109.34% to $5.9 million in 2024, then surged by 1209.39% to $77.5 million in 2025, then tumbled by 99.04% to $745000.0 in 2026.
• Business Quant data shows DTIL's Cash from Financing Activities at $745000.0 in Q1 2026, $77.5 million in Q4 2025, and $1.7 million in Q3 2025.